Financial Performance - Grant revenue for Q1 2024 was $0.569 million, an increase from $0.203 million in Q1 2023, representing a growth of 180.8%[14] - Total operating expenses for Q1 2024 were $9.348 million, down from $12.346 million in Q1 2023, a decrease of 24.3%[14] - Research and development expenses for Q1 2024 totaled $6.059 million, compared to $9.031 million in Q1 2023, reflecting a reduction of 32.8%[14] - Net loss for Q1 2024 was $8.388 million, or a net loss of $2.83 per share, compared to a net loss of $11.487 million, or $3.93 per share in Q1 2023, indicating an improvement of 26.5% in loss per share[14] Cash Position - As of March 31, 2024, cash, cash equivalents, and short-term investments totaled $27.027 million, down from $34.255 million as of December 31, 2023[12] - The company has a projected cash runway into Q1 2025, with no debt reported[5] Clinical Trials - The Phase 1/2 study of ONCT-534 for advanced prostate cancer is fully enrolled in the fourth dosing cohort at 300 mg per day, with initial data readout expected in Q2 2024[6] - The ROR1 CAR T Phase 1/2 study (ONCT-808) is open and enrolling patients, with clinical data update anticipated in mid-2024[6] Accumulated Deficit and Equity - The accumulated deficit as of March 31, 2024, was $206.167 million, an increase from $197.779 million as of December 31, 2023[12] - Total stockholders' equity decreased to $22.926 million as of March 31, 2024, from $30.052 million as of December 31, 2023[12]
Oncternal Therapeutics(ONCT) - 2024 Q1 - Quarterly Results